Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit

With increasing therapeutic options available for advanced hepatocellular carcinoma (HCC), the timing and sequencing of locoregional and systemic therapy need to be re-examined. This is especially so for patients with intermediate HCC, so as to optimize responses while preserving liver reserves, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, J.J.X., Tai, D.W.-M., Choo, S.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086015/
https://www.ncbi.nlm.nih.gov/pubmed/33887687
http://dx.doi.org/10.1016/j.esmoop.2021.100129
_version_ 1783686441992192000
author Lee, J.J.X.
Tai, D.W.-M.
Choo, S.P.
author_facet Lee, J.J.X.
Tai, D.W.-M.
Choo, S.P.
author_sort Lee, J.J.X.
collection PubMed
description With increasing therapeutic options available for advanced hepatocellular carcinoma (HCC), the timing and sequencing of locoregional and systemic therapy need to be re-examined. This is especially so for patients with intermediate HCC, so as to optimize responses while preserving liver reserves, and in so allowing our patients to achieve the best survival outcomes possible.
format Online
Article
Text
id pubmed-8086015
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80860152021-05-11 Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit Lee, J.J.X. Tai, D.W.-M. Choo, S.P. ESMO Open Review With increasing therapeutic options available for advanced hepatocellular carcinoma (HCC), the timing and sequencing of locoregional and systemic therapy need to be re-examined. This is especially so for patients with intermediate HCC, so as to optimize responses while preserving liver reserves, and in so allowing our patients to achieve the best survival outcomes possible. Elsevier 2021-04-20 /pmc/articles/PMC8086015/ /pubmed/33887687 http://dx.doi.org/10.1016/j.esmoop.2021.100129 Text en © 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Lee, J.J.X.
Tai, D.W.-M.
Choo, S.P.
Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
title Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
title_full Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
title_fullStr Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
title_full_unstemmed Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
title_short Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
title_sort locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086015/
https://www.ncbi.nlm.nih.gov/pubmed/33887687
http://dx.doi.org/10.1016/j.esmoop.2021.100129
work_keys_str_mv AT leejjx locoregionaltherapyinhepatocellularcarcinomawhentostartandwhentostopandwhentorevisit
AT taidwm locoregionaltherapyinhepatocellularcarcinomawhentostartandwhentostopandwhentorevisit
AT choosp locoregionaltherapyinhepatocellularcarcinomawhentostartandwhentostopandwhentorevisit

Ejemplares similares